登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
ClinicalTrials.gov 上登记的一项多发性骨髓瘤和B 细胞急性淋巴细胞白血病开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07113496,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Pathologically confirmed CD19-positive and/or B-cell maturation antigen (BCMA)-positive hematologic malignancy according to the WHO 2017 classification, including but not limited to multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphomas, and plasmablastic lymphoma.
入选标准第 2 条
Eastern Cooperative Oncology Group (ECOG) performance status 0-3.
入选标准第 13 条
Total bilirubin <2× upper limit of normal (ULN); serum creatinine <ULN; ALT and AST <3× ULN.
入选标准第 11 条
Absolute neutrophil count ≥0.5×10⁹/L; platelets ≥20×10⁹/L (no requirement if marrow involvement is documented).
入选标准第 12 条
For lymphoma: at least one measurable lesion ≥1.5 cm in longest diameter per IWG revised criteria.
入选标准第 6 条
Pregnancy, lactation, or planned pregnancy within 6 months.
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07113496,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntary participation with signed informed consent. Pathologically confirmed CD19-positive and/or B-cell maturation antigen (BCMA)-positive hematologic malignancy according to the WHO 2017 classification, including but not limited to multiple myeloma, B-cell acute lymphoblastic leukemia (B-ALL), mature B-cell lymphomas, and plasmablastic lymphoma. Relapsed/refractory disease defined as failure to achieve complete remission after standard therapy, or relapse after an initial response during treatment or follow-up. Measurable disease required: For B-ALL: persistent minimal residual disease (MRD) positivity despite hematologic remission. For lymphoma: at least one measurable lesion ≥1.5 cm in longest diameter per IWG revised criteria. For multiple myeloma: positive immunofixation electrophoresis or presence of extramedullary disease. Age ≥18 years; both sexes eligible. Expected survival ≥12 weeks. Adequate organ function (exceptions for disease-related impairment are at the investigator's discretion): Total bilirubin <2× upper limit of normal (ULN); serum creatinine <ULN; ALT and AST <3× ULN. Absolute neutrophil count ≥0.5×10⁹/L; platelets ≥20×10⁹/L (no requirement if marrow involvement is documented). Eastern Cooperative Oncology Group (ECOG) performance status 0-3. Left ventricular ejection fraction (LVEF) ≥50%.排除标准:Exclusion Criteria:
Known hypersensitivity, allergy, intolerance, or contraindication to CD19/BCMA-UCAR-T or any study drugs (fludarabine, cyclophosphamide, tocilizumab). Genetic syndromes: Fanconi, Kostmann, Shwachman, or any documented bone-marrow failure syndrome. Active or uncontrolled infection requiring IV antibiotics; evidence of severe active infection. NYHA Class III or IV heart failure (unless clearly secondary to the underlying malignancy). Central Nervous System (CNS) disorders unrelated to the primary hematologic malignancy. Prior malignancy except adequately treated carcinoma in situ of skin, cervix, lung, or other non-active tumors. Significant bleeding diathesis (e.g., gastrointestinal (GI) bleeding, coagulopathy, hypersplenism). History of significant cardiac disease within the past 3 months that, in the investigator's judgment, renders the patient unable to tolerate study participation.. Pregnancy, lactation, or planned pregnancy within 6 months. Any condition that, in the investigator's opinion, may increase risk or interfere with study results.
引自 ClinicalTrials.gov, NCT07113496, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07113496,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。